Gene Panel Market was valued at USD 2263.4 Million in 2022 and expected to reach USD 8157.6 Million by 2029 with the CAGR of 20.1% over the forecast period.
Global Gene Panel Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2029- Increasing prevalence of chronic diseases, rising number of product launches and growing demand for advanced medical testing are major factors anticipated to drive the Global Gene Panel Market.
The genetic test that analyzes multiple genes at once for cancer related mutations are called gene panel. Low muscle tone, short stature, or epilepsy are some of the examples of genetic panel test. Risk of developing breast or colon cancer associated genes can be also detected by Panel genetic tests. Early detection and rare genetic mutations that cause diseases can be predicted by gene panel. There two types of gene panel tests, in which targeted gene panels can be used for analysis of specific gene mutation associated with the disease while untargeted disease gene panel testing includes testing multiple genes to detect disabilities which are unpredictable. Gene Panel tests are also used for diagnosis of congenital disorders, cardiovascular diseases, pharmacogenetics and for cancer risk assessment.
The Covid-19 pandemic has shown a significant impact on the market growth of gene panel. As covid-19 virus was spreading diseases associated with Covid-19 infection such as arthritis, neurological diseases and cardiovascular diseases were also increasing, and gene panel tests can be used for the detection of such diseases thus, their demand was increased during pandemic. For instance; as per news published by National Centers for Biotechnology Information on November 4th, 2020 there have been reports of a stroke occurring in Covid-19 patients. Thus, demand of gene panel tests increased during pandemic due to detect Covid-19 associated cardiovascular diseases.
The global gene panel market is segmented into techniques, products & services, design, application, end-users and geography. On the basis of techniques, the market has been segmented into amplicon-based approach and hybridization-based approach. On the basis of products and services, the global gene panel market is segmented into test kits and testing services. On the basis of application, the market is segmented into cancer risk assessment, diagnosis of congenital disorders, pharmacogenetics and others. On the basis of end users, the global gene panel market has been segmented into hospital and diagnostic laboratories, research institutes and biotechnology and pharmaceutical companies.
The regions covered in global gene panel market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global gene panel market is subdivided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.
One of the major factors driving the growth of the global gene panel market is increasing prevalence of chronic diseases. Chronic diseases such as heart attack, arthritis, cancer these diseases anticipated to fuel the growth of the global gene panel market for the forecast period. Due to sedentary lifestyle and unhealthy eating, stress the prevalence of chronic diseases is increasing and which is driving demand for gene panel to detect the chronic diseases for clinical diagnostic tool. Thus, increasing cases of chronic disease is supplementing the global gene panel market growth. For instance; Centres for Disease Control and Prevention 6 in 10 people in U.S have chronic disease and as per World Health Organization over 795,000 people had heart attack in 2018 in U.S.
In addition, rising number of product launches by key players are also augumenting the market growth. As new product launches open opportunities and increase sale in the market. For instance; Ion AmpliSeq HD technology developed by Thermo Fisher Scientific to spot rare variants with new ultrahigh sensitivity gene panels in 2018. Furthermore, growing demand for advanced medical testing is also augumenting the market growth. The advanced techniques associated with the gene panel is driving demand as it provides medical testing along with options for personalized medicines. For the diagnosis of pharmacogenetics and congenital diseases, gene panel are extensively used. Research of targeted therapies for treating cancer also uses gene panels widely.
However, stringent regulation by government regarding the products in the pharmaceutical industries and growing concern regarding genetic data may hamper the market growth. In spite of that, growing research and development activities in this field may provide an opportunities for the further growth of the global gene panel market.
North America Expected to Dominate the Global Gene Panel Market
North America is expected to dominate the global gene panel market over the forecast period, due to rising number of chronic and infectious diseases, rising partnerships between market players and growing focus on research regarding rare diseases and genetic diseases in this region. For instance; there has been 87,673,034 confirmed cases in U.S from January 3rd, 2020 to 13th July 2022 of Covid-19. Hence, rising number of infectious and chronic diseases is driving demand of the global gene panel market in this region. In addition, rising partnerships in between the market players also adding growth to the market. For instance; 15-year partnership announced by Illumina, Inc., an American biotechnology company, and QIAGEN to enhance the distribution of next generation sequencing-based diagnostic kits to be used in conducting gene panels in October 2019. Moreover, growing focus and research in the field of rare diseases and genetic disorders is also boosting the market growth in this region.
Asia Pacific is anticipated to be a fastest growing market in global gene panel market growing cardiovascular diseases, rising demand for advanced technology, and increasing health care awareness in this region. For instance; as per National Center for Biotechnology Information (NCBI) stated that Global Burden of Disease study estimated that of CVD death rate of 272 per 100,000 population in India which is greater than the global average of 235 per 100,000 population. In addition, increasing health care awareness among population for early detection of diseases is also adding growth to the global gene panel market.
4baseCare Launched Indian Population Specific Cancer Gene Panel
August 17th, 2021; 4base Care a population specific tumour launched by Precision oncology company. Transcriptome data of over 1500 cancer patients across 28 different cancer types are used for the panel. Disease progression was presented by majorly by patients with stage III/ IV disease. The tumour tissues of Indian cancer patients have been used to TARGT Indigence cancer panel according to company. Mutational signatures identified in the in-cancer patients in India with the help of this research.
Biocartis Announced Launch of Its Rapid CE-marked IVD Idylla GeneFusion Panel for Fast Treatment Decisions in Lung Cancer
On June 20th, 2021; The CE-marking of its fully automated Idylla GeneFusion Panel (CE-IVD) announced by Biocartis Group NV an innovative molecular diagnostics company. This panel detects in one single cartridge METex14 skipping, ROS1, ALK and RET a widespread range of actionable targets relevant in non-small cell lung cancer (NSCLC). This panel can be intended for use in clinical laboratories, it provides the results within 180 minutes, significantly faster than currently available testing methods which often take days or even weeks before results are available.
Thermo Fisher Scientific Launched Ion AmpliSeq HD Technology
June 18th, 2018; Thermo Fisher Scientific announced the launch of its Ion AmpliSeq HD technology. This technology is based on next-generation sequencing. This technology provided to custom design gene panels without sacrificing the ultra-high sensitivity required to find low-frequency variants in cell-free DNA (cfDNA) and highly heterogeneous solid tumor samples.
|2018 - 2021
|2022 - 2029
|Market Size in 2021:
|USD 2263.4 Million
|Base year considered
|Forecast Period CAGR %:
|Market Size Expected in 2028:
|USD 8157.6 Million
|Tables, Charts & Figures:
|Gene Panel Companies
|Agilent Technologies, QIAGEN, Themo Fischer Scientific, GeneDx Inc, Eurofins Scientific, Illumina Inc. Novogene Co., Ltd. GATC Biotech, Invitae Corporation, Novogene Co., Ltd. and others.
|By Technique, By Products & Services, By Design, By Application, By End Users
|North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®